A recent study suggests that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a leading health publication points out that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users purchasing such medications must be informed of the potential of rapid weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
This pace of recovery implies a return to original weight in about a year and a half.
Analyzing Therapies
The study, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting typically have a more gradual creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the jabs is key to understanding the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to hunger is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the therapy is often long-term.
This view is supported by pharmaceutical companies, who state that the findings "underscore the chronic nature of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have discontinued the jabs explain a powerful resurgence of cravings.
"I experienced a trigger activating and I was suddenly starving," said an individual.
This challenge is compounded if patients have not developed sustainable lifestyle or habit changes during therapy.
Significant Adoption
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is greater among females than men.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on ongoing behavioural management.
